A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy
Conditions
EDS · Cataplexy · Fatigue · Narcolepsy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Phoenix Medical Group, PC, Peoria, Arizona, United States
Contact: Principal Investigator (Robert Orr, DO)Santa Monica Clinical Trials, Los Angeles, California, United States
Contact: Principal Investigator (Daniel Norman, MD)Alpine Clinical Research Center, Inc, Boulder, Colorado, United States
Contact: Principal Investigator (John R Harsh, PhD)PharmaDev Clinical Research Institute, LLC, Miami, Florida, United States
Contact: Principal Investigator (Edward Mezerhane, MD)Central Florida Pediatric Sleep Disorders Institute, Winter Park, Florida, United States
Contact: Principal Investigator (Akinyemi O Ajayi, MD)Neurotrials Research Inc, Atlanta, Georgia, United States
Sleep Practitioners, LLC, Macon, Georgia, United States
Contact: Principal Investigator (Charles C Wells, Jr, MD)Intrepid Research, LLC, Cincinnati, Ohio, United States
Contact: Principal Investigator (Bruce C Corser, MD)Respiratory Specialists, Wyomissing, Pennsylvania, United States
Contact: Principal Investigator (Alec Platt, MD)Lowcountry Lung and Critical Care PA, Charleston, South Carolina, United States
Contact: Principal Investigator (Thomas D Kaelin Jr, DO)Bogan Sleep Consultants, LLC, Columbia, South Carolina, United States
Contact: Principal Investigator (Richard Bogan, MD)Southwest Family Medicine, Dallas, Texas, United States
Contact: Principal Investigator (Chrisette Dharma, MD)Sleep Therapy & Research Center, San Antonio, Texas, United States
Contact: Principal Investigator (Nagwa Lamaie, MD)Sleep and Performance Research Center, Spokane, Washington, United States
Contact: Principal Investigator (Devon Hansen, PhD)
Study leads
David Seiden, MD
Study Director
Harmony Biosciences Management, Inc.